Several eminent scientists and medical professionals are stressing the FDA to advise vaccine producers to a perform T-cell evaluation in COVID-19 vaccine clinical trials to more thoroughly examine the immune response. They emphasized that to more accurately assess vaccination efficacy and make judgments regarding continued protection against present and future variants, it was important to measure the T-cell responses in addition to antibodies.

Protection includes Infection prevention and the prevention of serious sickness from infection. Evasion of antibody responses has been observed by the Omicron and Delta variants. But, the appearance of the Omicron variants has prompted researchers to examine the role of T cells in balancing the loss of antibody-mediated defence. According to numerous studies, the vaccine-induced T-cell response against this variation is still present, thus maintaining the vaccine′s effectiveness.

Numerous studies have also revealed that antibodies might not be enough to offer serious disease protection on its alone. Hence evaluating only the humoral aspect of the adaptive immune response was not sufficient on the other hand T cell responses have been reported to provide loner protection compared to serum neutralizing antibody titers. (News-medical.net, Aug 11 2022)